vTv Therapeutics (VTVT) Other Non-Current Assets (2014 - 2026)

vTv Therapeutics (VTVT) posted Other Non-Current Assets of $5000.0 for Q1 2026, down 16.67% sequentially from $6000.0 in Q4 2025.

vTv Therapeutics (VTVT) Other Non-Current Assets (2014 - 2026) Analysis & Trends

vTv Therapeutics has reported Other Non-Current Assets for 10 years, with the latest figure at $5000.0 in Q1 2026.

Quarterly Other Non-Current Assets changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (changed N/A YoY) and the FY2025 annual result came in at $6000.0, down 96.08% from the prior year.
Other Non-Current Assets eased to $5000.0 in Q1 2026 per VTVT's latest filing, from $6000.0 in the prior quarter.
Over five years, Other Non-Current Assets peaked at $153000.0 in Q4 2024 and troughed at $5000.0 in Q1 2026.
A 3-year average of $54666.7 and a median of $6000.0 in 2025 frame the typical range for Other Non-Current Assets.
The widest YoY moves for Other Non-Current Assets: up 96.08% in 2025, down 96.08% in 2025.
Over 3 years, Other Non-Current Assets stood at $153000.0 in 2024, then tumbled by 96.08% to $6000.0 in 2025, then fell by 16.67% to $5000.0 in 2026.
According to Business Quant data, Other Non-Current Assets over the past three periods registered $5000.0, $6000.0, and $153000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	124.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	42.45 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	109.58 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	18,237.65
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	62.96 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	65.13 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	104.44 Mn
10	vTv Therapeutics	373.77 Mn	373.77 Mn	-	4,000.00

Download Data